Category: Tengion Inc.
Here's a look at some of the top regulatory stories for medical device companies this week: New inversion rules unlikely to scuttle Medtronic's $43B Covidien buy; New U.S. tax rules may lead Medtronic to redo inversion deal; Ackman threatens to sue Allergan again over potential Salix deal; Tengion is on the auction block
Tengion puts itself and its organ regeneration technology on the auction block, hiring Jefferies LLC to explore "strategic alternatives."
Tengion, TNGN, Jefferies, organ regeneration, kidney
Tengion (NSDQ:TNGN) said it's hired Jefferies to assess "all strategic alternatives," corporate shorthand for putting the Winston-Salem, N.C.-based company and its organ regeneration technology on the auction block.
Tengion posts greater losses during the 2nd quarter as it develops its human organ transplant technology, but rakes in more than $30M in investments.
Tengion (NSDQ:TNGN) almost tripled its losses in the 2nd quarter, but raked in more than $30 million in investments for its human organ regeneration technology.
Tengion Inc. raises $74.3 million to back its Neo-Kidney Augment and Neo-Urinary Conduit clinical programs.
Tengion (NSDQ:TNGN) said it raised $74.3 million from 22 unnamed investors as it puts a pair of clinical programs through their paces.
The Winston-Salem, N.C.-based medical device company is developing the Neo-Kidney Augment and Neo-Urinary Conduit, human organs that are grown using a bioabsorbable scaffold and patients' own cells.
Tengion Inc. raises $33.6 million from a pair of investors supporting its Neo-Kidney Augment and Neo-Urinary Conduit clinical programs.
North Carolina regenerative medicine company Tengion (NSDQ:TNGN) raised $33.6 million in support of clinical studies of its leading programs, the Neo-Kidney Augment and Neo-Urinary Conduit programs. TNGN shares jumped 15.3% to 68¢ around 12:40 p.m. today, up from an opening price of 64¢.
Tengion's clinical trial of its Neo-Urinary Conduit system will continue after 2 of the 6 enrolled patients died from causes unrelated to the trial.
Tengion (NSDQ:TNGN) plans to complete enrollment its in Neo-Urinary Conduit clinical trial following the deaths of 2 of the 6 enrolled patients after deeming the deaths unrelated to the device or surgical procedure.
Medtronic touts news study results comparing its Resolute drug-eluting stent in patients with and without diabetes; also, Tengion struggles, but may find refuge in Medtronic; Uroplasty soars on 40% boost in Q4 sales; NeuroMetrix targets investors; Allscripts shareholders launch proxy war; plus, a Funding Roundup and analysts' ups and downs.
Medtronic (NYSE:MDT) touted new study results for its Resolute drug-eluting stents, the 1st with FDA indication for treatment of patients with diabetes.